Received Oct 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (INFANRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| DTAPHEPBIP | DTAP + HEPB + IPV (PEDIARIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
| RV1 | ROTAVIRUS (ROTARIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Vaccines administered to patients after above temperature excursion; This non-serious case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a patient who received HBV (Engerix B) for prophylaxis. Co-suspect products included Rota (Rotarix liquid formulation) for prophylaxis, HAV (Havrix) for prophylaxis, DTPa (Reduced antigen) (Boostrix) for prophylaxis, Men B NVS (Bexsero) for prophylaxis, Men ACWY-CRM NVS (Menveo) for prophylaxis, DTPa (Infanrix) for prophylaxis, DTPa-IPV (Kinrix) for prophylaxis and DTPa-HBV-IPV (Pediarix) for prophylaxis. On an unknown date, the patient received Engerix B, Rotarix liquid formulation, Havrix, Boostrix, Bexsero, Menveo, Infanrix, Kinrix and Pediarix. On an unknown date, an unknown time after receiving Engerix B, Rotarix liquid formulation, Havrix, Boostrix, Bexsero, Menveo, Infanrix, Kinrix and Pediarix, the patient experienced incorrect storage of drug (Verbatim: Vaccines administered to patients after above temperature excursion). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt date: 01-OCT-2025 Medical Assistant called to report an above temperature excursion for Pediarix, Kinrix, Infanrix, Menveo (1-vial), Bexsero, Boostrix, Havrix, Rotarix (liquid), Engerix-B, on 5th May 2025, but noticed until 29th September 2025. The highest temperature reached was 63 degrees fahrenheit, and duration was 1 hour, with no prior excursions reported. Reporter mentioned that the vaccines were administered to patients after the excursion happened. The batch number was not provided upon follow- up with the reporter.